Glycomimetics inc (GLYC)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13
Assets
Current assets:
Cash and cash equivalents

154,823

158,201

170,886

184,167

195,560

209,917

219,828

229,434

242,632

123,924

112,872

119,147

34,590

40,041

45,282

53,085

38,830

46,802

53,759

40,234

46,566

55,198

61,362

66,217

56,966

2,310

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20,000

-

-

-

-

-

-

Prepaid expenses and other current assets

2,058

4,326

3,909

2,301

2,828

2,351

2,605

3,483

3,477

3,294

1,015

502

697

478

1,239

1,449

683

441

718

534

777

916

587

881

719

2,573

Total current assets

156,881

162,527

174,796

186,468

198,389

212,269

222,433

232,918

246,109

127,219

113,888

119,650

35,287

40,520

46,522

54,534

39,513

47,244

54,478

60,769

47,343

56,115

61,949

67,098

57,685

4,883

Property and equipment, net

762

822

878

929

962

957

968

1,010

1,054

1,106

1,122

1,159

1,074

1,056

676

487

491

521

567

579

420

452

481

420

379

399

Prepaid research and development expenses

1,560

1,560

1,560

1,560

1,560

1,560

1,714

1,714

204

204

759

759

759

759

759

696

696

696

696

696

696

696

-

-

-

-

Deposits

52

52

52

52

52

52

52

52

52

52

52

52

52

52

52

52

-

-

-

-

-

-

-

-

-

-

Operating lease right-of-use asset

2,841

3,006

3,166

3,323

3,476

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total assets

162,099

167,969

180,454

192,334

204,441

214,839

225,169

235,695

247,420

128,583

115,822

121,621

37,174

42,388

48,010

55,771

40,701

48,462

55,741

62,044

48,460

57,263

62,431

67,519

58,064

5,283

Liabilities & stockholders' equity
Current liabilities:
Accounts payable

3,134

1,435

1,407

3,026

1,866

2,663

659

3,239

3,853

2,647

1,631

575

511

1,565

1,246

1,397

1,622

564

633

1,106

1,183

874

583

472

1,797

1,144

Accrued bonuses

-

-

1,645

1,082

517

-

1,293

852

441

1,883

1,146

766

387

1,432

826

552

276

1,037

695

446

226

753

568

372

177

344

Accrued expenses

6,651

8,710

6,599

5,762

5,182

6,000

4,388

2,859

4,318

3,566

3,678

4,034

3,563

3,267

3,263

4,063

3,784

6,145

5,521

5,204

2,626

4,735

3,445

2,640

559

685

Operating lease liabilities

826

804

783

761

739

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

98

92

86

82

78

74

70

70

68

81

81

-

-

-

38

67

97

115

111

107

104

Total current liabilities

10,612

10,950

10,436

10,632

8,306

8,763

6,434

7,037

8,695

8,174

6,530

5,447

4,533

6,333

5,417

6,094

5,683

7,746

6,850

6,796

4,103

6,460

4,713

3,596

2,642

2,279

Noncurrent accrued expenses

393

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncurrent operating lease liabilities

2,603

2,818

2,937

3,143

3,341

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent, net of current portion

-

-

-

-

-

611

639

663

685

707

726

742

754

753

841

799

250

243

186

28

-

-

9

38

67

96

Total liabilities

13,609

13,769

13,373

13,775

11,647

9,374

7,073

7,701

9,381

8,881

7,257

6,189

5,287

7,087

6,259

6,894

5,933

7,990

7,036

6,824

4,103

6,460

4,723

3,635

2,709

2,376

Stockholders' equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2019 and December 31, 2018

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

-

0

-

0

0

-

0

0

0

0

Common stock; $0.001 par value; 100,000,000 shares authorized, 43,582,979 shares issued and outstanding at March 31, 2020; 100,000,000 shares authorized, 43,466,933 shares issued and outstanding at December 31, 2019

43

43

43

43

43

43

43

43

42

34

32

32

23

23

23

23

19

19

19

19

19

18

18

18

18

1

Additional paid-in capital

414,551

412,599

410,753

408,980

407,385

405,972

404,696

403,020

401,786

271,944

251,550

250,468

158,789

154,254

152,375

151,646

129,470

127,619

126,970

126,317

125,844

125,181

124,692

124,250

123,712

66,150

Accumulated deficit

-266,105

-258,442

-243,716

-230,464

-214,634

-200,550

-186,643

-175,068

-163,789

-152,277

-143,019

-135,069

-126,927

-118,976

-110,647

-102,793

-94,721

-87,166

-78,284

-71,116

-81,506

-74,396

-67,003

-60,385

-

-63,275

Deficit accumulated during the development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

68,377

-

Total stockholders' equity

148,490

154,200

167,080

178,558

192,793

205,464

218,095

227,994

238,039

119,701

108,564

115,431

31,886

35,301

41,751

48,876

34,767

40,471

48,704

55,219

44,357

50,803

57,708

63,883

55,354

2,907

Total liabilities and stockholders' equity

162,099

167,969

180,454

192,334

204,441

214,839

225,169

235,695

247,420

128,583

115,822

121,621

37,174

42,388

48,010

55,771

40,701

48,462

55,741

62,044

48,460

57,263

62,431

67,519

58,064

5,283